Background: To estimate HIV incidence several methods have been used to discriminate recent HIV infections from long-standing infections using a single serum sample.
Objective: To evaluate the performance of the anti-HIV avidity index (AI) for identifying recent HIV infections in individuals with a known date of seroconversion from Uganda, where the predominant HIV subtypes are A and D.
Study Design: We selected 149 repository serum samples from Ugandan HIV-positive individuals and evaluated the AI. Specimens collected < or =6 months after seroconversion were considered as recent infections, and those collected >6 months as long-standing infections. All specimens were serotyped using a V3 peptide enzyme immunoassay.
Results: The mean AI was 0.55+/-0.21 among the 108 patients with recent infections and 0.93+/-0.14 among the 41 samples from long-standing infections (p<0.0001). The AI test showed a sensitivity of 85.2% and a specificity of 85.4% at a cutoff of 0.80. No significant association was observed between serotype and the misclassification of samples by AI.
Conclusions: The AI, which is inexpensive and easy-to-perform, can be useful in identifying recent HIV infections in countries where HIV-1 non-B subtypes are prevalent.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jcv.2007.11.020 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
HIV and Inflamm-Aging: How Do We Reach the Summit of Healthy Aging?
Top Antivir Med
December 2024
University of Minnesota, Minneapolis, USA.
People with HIV (PWH) are living longer and experiencing a greater burden of morbidity from non-AIDS-defining conditions. Chronically treated HIV disease is associated with ongoing systemic inflammation that contributes to the development of chronic conditions (eg, cardiovascular disease) and geriatric syndromes (eg, frailty). Apart from HIV disease, a progressive increase in systemic inflammation is a characteristic feature of biologic aging, a process described as "inflammaging.
View Article and Find Full Text PDFWeighing In: Glucagon-Like Peptide-1 Receptor Agonism for Persons With HIV.
Top Antivir Med
December 2024
Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Weight gain among persons with HIV PWH) on contemporary antiretroviral therapy (ART) can extend beyond an initial return-to-health phenomenon and lead to overweight/obesity in the first 1 to 2 years, resulting in enhanced cardiometabolic risk. Factors that may contribute to increased weight gain include specific ART regimens (those initiating dolutegravir and tenofovir alafenamide or withdrawing tenofovir disoproxil and efavirenz), women with HIV, and certain virologic factors including lower baseline CD4 count and higher HIV viral load. Weight reduction starting at 5% body weight confers metabolic protection, such as improved hypertension and dysglycemia.
View Article and Find Full Text PDFManaging Stimulant Use Among People With HIV: Harm-Reduction Strategies From Behavior to Medication.
Top Antivir Med
December 2024
University of California Los Angeles, Los Angeles, California, USA.
Stimulant use disorder poses substantial challenges to the health and well-being of people with HIV, contributing to increased HIV transmission risk and poor clinical outcomes. This article highlights the cultural significance of stimulant use, its epidemiology, and the latest evidencebased interventions for stimulant use disorder among individuals with HIV. Contingency management has emerged as the most effective treatment, with harm-reduction approaches serving as vital tools for improving the health of individuals unable or unwilling to achieve abstinence.
View Article and Find Full Text PDFPrevalence and incidence of HPV-related dysplasia of oropharyngeal, cervical, and anal mucosae in Spanish people living with HIV (PLHIV).
AIDS
January 2025
Internal Medicine Department, Hospital Universitario Virgen de las Nieves, Instituto de Investigación Biosanitario de Granada (IBS-Granada), Spain.
Background: Objectives were to determine the prevalence/incidence of HPV-related dysplasia and clearance/acquisition rates of high-risk HPV (HR-HPV) genotypes in genital mucosa of women-LHIV and oropharyngeal and anal mucosa of PLHIV and to evaluate factors related to HR-HPV infection in oropharyngeal mucosa at 12-months.
Material And Methods: Prospective, longitudinal study with 12-month follow-up, enrolled PLHIV between December 2022 and April 2023. At baseline and 12-months, HIV-related clinical and analytical variables were recorded, oropharyngeal mucosa exudates were taken for polymerase chain reaction (PCR) studies for HPV and other sexually transmitted infections, while anal and female genital samples were self-sampled for HPV detection and genotyping by PCR and thin-layer cytology.
HIV interventions across the care continuum for adolescents in high-burden countries: a systematic review and meta-analysis.
EClinicalMedicine
December 2024
University of North Carolina Project-China, Guangzhou, China.
Background: Adolescents (10-19 years old) have poor outcomes across the prevention-to-treatment HIV care continuum, leading to significant mortality and morbidity. We conducted a systematic review and meta-analysis of interventions that documented HIV outcomes among adolescents in HIV high-burden countries.
Methods: We searched PubMed, EMBASE, Scopus, and the Cochrane Library for studies published between January 2015 and September 2024, assessing at least one HIV outcome along the prevention-to-care cascade, including PrEP uptake, HIV testing, awareness of HIV infections, ARV adherence, retention, and virological suppression.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!